Clinical Trial Update: CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabazitaxel with or without prednisone in metastatic castration-resistant prostate cancer after prior docetaxel therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: UNKNOWN